Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yuhan Corporation (000100.KS)
Seoul, KR
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | -0.82% | -8.80% | -22.87% | -30.33% | -24.65% | -19.35% | +49.00% | +49.77% | +99.02% | +2,303.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | -1 |
| Buy | 10 | +1 |
| Hold | 2 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.8% Q1'26: +7.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+175.6% ★ Q1'26: +207.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.8% Q1'26: +3.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.8% Q1'26: +1.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.8% Q1'26: +1.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+8.3% Q1'26: +8.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.97× ★ Q1'26: 3.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 7 EPS Ana. |
Dec 2027 19 Rev. Ana. 16 EPS Ana. |
Dec 2028 8 Rev. Ana. 15 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.13T
est: 1.12T (+0.9%)
|
1.32T
est: 1.30T (+1.7%)
|
1.46T
est: 1.45T (+0.9%)
|
1.52T
est: 1.50T (+1.0%)
|
1.48T
est: 1.50T (-1.1%)
|
1.62T
est: 1.61T (+0.8%)
|
1.69T
est: 1.70T (-0.6%)
|
1.78T
est: 1.79T (-0.6%)
|
1.86T
est: 1.90T (-2.1%)
|
2.07T
est: 2.08T (-0.7%)
|
2.19T
est: 2.23T (-1.8%)
|
2.34T
2.27T – 2.42T
+5.1% YoY
|
2.57T
2.35T – 2.87T
+10.0% YoY
|
2.82T
2.65T – 3.04T
+9.6% YoY
|
| EBITDA |
116.89B
est: 89.69B (+30.3%)
|
140.71B
est: 104.06B (+35.2%)
|
201.73B
est: 116.17B (+73.7%)
|
109.13B
est: 120.55B (-9.5%)
|
69.65B
est: 119.94B (-41.9%)
|
238.89B
est: 128.78B (+85.5%)
|
123.92B
est: 136.08B (-8.9%)
|
78.07B
est: 143.26B (-45.5%)
|
127.43B
est: 152.12B (-16.2%)
|
139.20B
est: 138.72B (+0.3%)
|
174.47B
est: 148.29B (+17.7%)
|
155.85B
150.89B – 161.43B
+5.1% YoY
|
171.46B
156.49B – 190.87B
+10.0% YoY
|
187.92B
176.42B – 202.35B
+9.6% YoY
|
| EBIT |
171.48B
est: 56.82B (+201.8%)
|
210.22B
est: 65.92B (+218.9%)
|
149.54B
est: 73.59B (+103.2%)
|
93.06B
est: 76.37B (+21.9%)
|
10.99B
est: 75.99B (-85.5%)
|
179.10B
est: 81.58B (+119.5%)
|
71.25B
est: 86.21B (-17.4%)
|
35.05B
est: 90.75B (-61.4%)
|
82.75B
est: 96.37B (-14.1%)
|
76.16B
est: 79.75B (-4.5%)
|
105.31B
est: 85.25B (+23.5%)
|
89.60B
86.74B – 92.80B
+5.1% YoY
|
98.57B
89.96B – 109.73B
+10.0% YoY
|
108.03B
101.42B – 116.33B
+9.6% YoY
|
| Net Income |
126.05B
est: 111.69B (+12.9%)
|
161.25B
est: 103.99B (+55.1%)
|
109.03B
est: 115.67B (-5.7%)
|
57.48B
est: 70.76B (-18.8%)
|
40.01B
est: 51.44B (-22.2%)
|
192.76B
est: 202.01B (-4.6%)
|
102.58B
est: 98.66B (+4.0%)
|
95.14B
est: 84.63B (+12.4%)
|
136.20B
est: 74.05B (+83.9%)
|
70.69B
est: 124.97B (-43.4%)
|
194.08B
est: 122.39B (+58.6%)
|
145.12B
115.07B – 214.33B
+18.6% YoY
|
202.65B
107.57B – 363.75B
+39.6% YoY
|
244.17B
224.74B – 268.55B
+20.5% YoY
|
| SGA |
104.52B
est: 138.93B (-24.8%)
|
124.70B
est: 161.19B (-22.6%)
|
139.36B
est: 179.95B (-22.6%)
|
144.94B
est: 186.74B (-22.4%)
|
162.38B
est: 185.80B (-12.6%)
|
154.76B
est: 199.48B (-22.4%)
|
190.51B
est: 210.79B (-9.6%)
|
200.40B
est: 221.91B (-9.7%)
|
370.03B
est: 235.64B (+57.0%)
|
207.66B
est: 255.19B (-18.6%)
|
191.25B
est: 272.79B (-29.9%)
|
286.70B
277.57B – 296.96B
+5.1% YoY
|
315.41B
287.88B – 351.12B
+10.0% YoY
|
345.70B
324.54B – 372.25B
+9.6% YoY
|
| EPS |
1,743.59
est: 1,490.04 (+17.0%)
|
2,343.71
est: 1,387.33 (+68.9%)
|
1,594.63
est: 1,543.08 (+3.3%)
|
831.92
est: 943.98 (-11.9%)
|
553.86
est: 686.21 (-19.3%)
|
2,545.07
est: 2,694.88 (-5.6%)
|
1,357.03
est: 1,316.19 (+3.1%)
|
1,206.67
est: 1,129.06 (+6.9%)
|
1,816.00
est: 987.92 (+83.8%)
|
943.00
est: 1,540.00 (-38.8%)
|
2,599.00
est: 1,508.23 (+72.3%)
|
1,788.33
1,417.96 – 2,641.23
+18.6% YoY
|
2,497.21
1,325.62 – 4,482.54
+39.6% YoY
|
3,008.93
2,769.52 – 3,309.33
+20.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-14 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wook-Je Cho | President, Chief Executive Officer & Executive Director | 1B | male |
| Yeul-Hong Kim | President, R&D Director & Executive Director | 781M | male |
| Joo-Yong Chung | MD & Head of Marketing Department | — | male |
| Jun-Hwan Kim | MD & Head of Biopharmaceutical Division | — | male |
| Byung-Man Lee | VP, Head of the Mngt. HQ. & Internal Accounting Manager | — | male |
| Sung-Soo Kim | MD & Head of the Lifestyle Health Business Division | — | male |
| Min Chul Cho | MD & ESG Management Director | — | male |
| Jae-Kyo Kim | VP & Head of the Pharmaceutical Business Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000100.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
